Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some claims (e.g., indication/use and general concept of lowering blood Phe in BH4-responsive PKU) are supported by the provided label excerpts, but several adverse reaction and interaction details are not verifiable from the supplied prescribing information text. Additional inaccuracies are present regarding the product compared (JAVYGTOR vs Kuvan) and the availability/expiration assertions are not label-supported in the provided excerpts.
Category Scores
Accurate Statements
Sapropterin helps the body process phenylalanine.
Supported indirectly by label mechanism of action: “Sapropterin dihydrochloride is a synthetic form of BH4… Treatment with BH4 can activate residual PAH enzyme activity… and decrease Phe levels in some patients.” (Section 12.1)
Low blood phenylalanine levels are a rare but serious side effect of sapropterin.
Supported in concept that low Phe occurs during treatment: “In clinical trials… some PKU patients experienced hypophenylalaninemia (low blood Phe) during treatment…” (Section 5.3). Also relates to monitoring/serious consequences: Section 5.4 discusses risks of too-low Phe levels.
Low blood phenylalanine levels from sapropterin can lead to seizures.
Partially supported by label safety concept regarding too-low blood Phe levels being associated with serious outcomes, but the provided excerpt does not explicitly state seizures.
Sapropterin may interact with methotrexate.
Provided label excerpt indicates a drug interaction table exists: “Table 4 includes drugs with clinically important drug interactions…” but the excerpt does not list methotrexate.
Sapropterin may interact with levodopa.
Provided label excerpt indicates a drug interaction table exists: “Table 4 includes drugs with clinically important drug interactions…” but the excerpt does not list levodopa.
Sapropterin (Kuvan) is used to treat phenylketonuria.
Supported as the label indication is for PKU/HPA due to BH4-responsive PKU, and uses the drug name JAVYGTOR (sapropterin dihydrochloride). Provided excerpt: “indicated… with… BH4-responsive Phenylketonuria (PKU).” (Section 1)
Unsupported Statements
Headache is a reported side effect of sapropterin.
The provided label excerpts under Adverse Reactions (Section 6) do not list specific symptoms such as headache.
Runny nose is a reported side effect of sapropterin.
The provided label excerpts do not list specific adverse reactions such as runny nose.
Sore throat is a reported side effect of sapropterin.
The provided label excerpts do not list specific adverse reactions such as sore throat.
Diarrhea is reported as a possible gastrointestinal effect associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as diarrhea.
Vomiting is reported as a possible gastrointestinal effect associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as vomiting.
Abdominal pain is reported as a possible gastrointestinal effect associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as abdominal pain.
Cough is reported as a possible respiratory symptom associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as cough.
Nasal congestion is reported as a possible respiratory symptom associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as nasal congestion.
Fatigue is reported as a side effect associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as fatigue.
Fever is reported as a side effect associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as fever.
Rash is reported as a side effect associated with sapropterin.
The provided label excerpts do not list specific adverse reactions such as rash.
Low blood phenylalanine levels from sapropterin can lead to seizures.
Section 5.4 excerpt provided mentions severe neurologic damage and catabolism risks, but does not explicitly mention seizures.
Low blood phenylalanine levels from sapropterin can lead to neurological damage if not managed.
The provided label excerpt supports neurologic damage risk for prolonged elevations of blood Phe and also discusses risks when blood Phe is too low, but does not explicitly connect “if not managed” to the “too low” mechanism beyond the active management and monitoring requirement; this is only partially evidenced in the excerpt.
Low blood sugar levels are reported as a rare side effect associated with sapropterin.
The provided label excerpts do not mention hypoglycemia/low blood sugar.
Allergic reactions are reported as a rare side effect associated with sapropterin.
The provided label excerpts do not mention allergic reactions.
Sapropterin may interact with methotrexate.
The excerpt confirms a drug interaction table exists but does not provide the specific interacting drugs; methotrexate is not listed in the provided text.
Sapropterin may interact with levodopa.
The excerpt confirms a drug interaction table exists but does not provide the specific interacting drugs; levodopa is not listed in the provided text.
The patent for sapropterin as Kuvan expired in 2015.
The provided FDA label excerpts do not address patent status or expiration dates.
Biosimilars and generics are now available for sapropterin.
The provided FDA label excerpts do not address availability of generics/biosimilars.
Contradictions
Low
AI Statement
The patent for sapropterin as Kuvan expired in 2015.
Label Reference
No patent/expiration information is provided in the label excerpts.
Important Omissions
Dose and administration details (e.g., dosing range, meal administration, evaluation period, and blood Phe monitoring schedule) are not provided in the AI response, though the user did not ask for dosing.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or unverifiable claims about specific adverse reactions and specific drug interactions (e.g., methotrexate/levodopa) could mislead decision-making. The label excerpts do support the need for monitoring blood Phe and discuss risks related to low Phe, but several safety details in the AI response are not evidenced by the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several adverse reaction and interaction specifics (and Kuvan patent/generic availability statements) are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported content from the provided excerpts (indication to reduce blood Phe in BH4-responsive PKU and requirement for Phe-restricted diet and blood Phe monitoring; for adverse reactions, use only reactions explicitly listed in the provided label text; for interactions, avoid naming specific drugs unless they are explicitly listed in the provided interaction table excerpt; remove non-label patent/generic availability statements).